Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kinase inhibitors: vice becomes virtue.

Peter K Vogt1, Sohye Kang

  • 1Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA. pkvogt@scripps.edu

Cancer Cell
|May 16, 2006
PubMed
Summary

A new dual inhibitor of PI3 kinase (PI3K) and TOR effectively halts glioma cell growth. This single-agent therapy targets both p110alpha and TOR, overcoming feedback loops resistant to single-target drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The constitutive oncogenic and signaling activities of phosphatidylinositol 3-kinase (PI3K) isoforms p110β and p110δ.

bioRxiv : the preprint server for biology·2025
Same author

Long Non-Coding RNAs as "MYC Facilitators".

Pathophysiology : the official journal of the International Society for Pathophysiology·2023
Same author

Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field.

Journal of medicinal chemistry·2023
Same author

Structural insights into the interaction of three Y-shaped ligands with PI3Kα.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same author

Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα).

Biochimica et biophysica acta. Reviews on cancer·2023
Same author

The MYC-regulated lncRNA LNROP (ENSG00000254887) enables MYC-driven cell proliferation by controlling the expression of OCT2.

Cell death & disease·2023

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
  • The PI3K/AKT/mTOR pathway is frequently dysregulated in GBM, driving tumor growth and survival.
  • Monospecific inhibitors targeting PI3K or mTOR alone are often limited by feedback mechanisms.

Purpose of the Study:

  • To identify and characterize a novel inhibitor targeting both PI3K and mTOR.
  • To evaluate the efficacy of this dual inhibitor in preclinical models of glioma.
  • To elucidate the mechanism of action of the dual inhibitor.

Main Methods:

  • Synthesis and characterization of a novel small molecule inhibitor.
  • In vitro assays assessing inhibition of PI3K (p110alpha) and mTOR.
  • Cell viability and proliferation assays using glioma cell lines.
  • Western blot analysis to assess pathway modulation and feedback inhibition.

Main Results:

  • The novel inhibitor demonstrated potent dual activity against p110alpha and TOR.
  • The compound effectively inhibited the growth of multiple glioma cell lines.
  • Dual inhibition synergistically overcame feedback loops that confer resistance to monospecific agents.
  • The inhibitor achieved combination therapy effects as a single agent.

Conclusions:

  • A novel dual PI3K/mTOR inhibitor shows significant preclinical efficacy against glioma.
  • Targeting both PI3K (p110alpha) and TOR simultaneously is a promising strategy for overcoming therapeutic resistance.
  • This single-agent approach offers a potential advantage over combination therapies for treating glioma.

Related Experiment Videos